From: Targeted therapy in advanced non-small cell lung cancer: current advances and future trends
mTOR/PI3K pathway Inhibitors | ||||
---|---|---|---|---|
Drug name | Mechanism of action | Clinical trial (Phase) | Study design | Disease |
Gedatolisib (PF-05212384) | pan-PI3K/mTOR inhibitor | NCT03065062 (1) | Combination with Palbociclib | Advanced tumors including squamous NSCLC |
Idelalisib | PI3K inhibitor | NCT03257722 (1) | Combination with Pembrolizumab | Advanced NSCLC with progression on first line therapy |
Nab Rapamycin (ABI-009) | mTOR inhibitor | NCT03190174 (1/2) | Combination with Nivolumab | Advanced solid tumors including NSCLC |
RMC-5552 | bi-steric mTORC1-selective inhibitor | NCT04774952 (1/1b) | Monotherapy | Advanced solid tumors including NSCLC |
Sapanisertib | mTORC1/mTORC2 inhibitor | NCT02417701 (2) | Monotherapy | KRAS mutant NSCLC with KEAP1 mutation |
Sirolimus | mTOR inhibitor | NCT01737502 (1/2) | Combination with Auranofin | Advanced or Recurrent Lung Cancer |